These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 10794103)

  • 21. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
    Vicari G
    Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for viral removal and inactivation.
    Burstyn DG; Hageman TC
    Dev Biol Stand; 1996; 88():73-9. PubMed ID: 9119165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
    Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
    Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a microporous polyvinylidene fluoride (PVDF) membrane filter to separate contaminating viral particles from biologically important proteins.
    Oshima KH; Evans-Strickfaden TT; Highsmith AK; Ades EW
    Biologicals; 1996 Jun; 24(2):137-45. PubMed ID: 8889061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient removal of viruses by a novel polyvinylidene fluoride membrane filter.
    Roberts P
    J Virol Methods; 1997 Apr; 65(1):27-31. PubMed ID: 9128859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A validatable membrane-based system for the removal of viruses from biopharmaceuticals.
    Sekhri PJ; Levy RV
    Am Biotechnol Lab; 1992 Feb; 10(1):53. PubMed ID: 1367874
    [No Abstract]   [Full Text] [Related]  

  • 29. Proceedings of the 2017 Viral Clearance Symposium, Session 2.1: DSP Unit Operations-Virus Filtration/Inactivation.
    Kreil TR; Roush D
    PDA J Pharm Sci Technol; 2018; 72(5):470-478. PubMed ID: 30030356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phage passage after extended processing in small-virus-retentive filters.
    Lute S; Bailey M; Combs J; Sukumar M; Brorson K
    Biotechnol Appl Biochem; 2007 Jul; 47(Pt 3):141-51. PubMed ID: 17286554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus filtration of high-concentration monoclonal antibody solutions.
    Marques BF; Roush DJ; Göklen KE
    Biotechnol Prog; 2009; 25(2):483-91. PubMed ID: 19353736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration.
    Maerz H; Hahn SO; Maassen A; Meisel H; Roggenbuck D; Sato T; Tanzmann H; Emmrich F; Marx U
    Nat Biotechnol; 1996 May; 14(5):651-2. PubMed ID: 9630961
    [No Abstract]   [Full Text] [Related]  

  • 35. Removal of virus through novel membrane filtration method.
    Manabe S
    Dev Biol Stand; 1996; 88():81-90. PubMed ID: 9119166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).
    Azari M; Boose JA; Burhop KE; Camacho T; Catarello J; Darling A; Ebeling AA; Estep TN; Pearson L; Guzder S; Herren J; Ogle K; Paine J; Rohn K; Sarajari R; Sun CS; Zhang L
    Biologicals; 2000 Jun; 28(2):81-94. PubMed ID: 10885615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Viral safety of biological products and the concept of validation.
    Horaud F
    Dev Biol Stand; 1996; 88():19-24. PubMed ID: 9119135
    [No Abstract]   [Full Text] [Related]  

  • 38. Sorption of bacterial endotoxin and retention of bacteria by positively charged membrane filters.
    van Doorne H
    J Parenter Sci Technol; 1993; 47(5):192-8. PubMed ID: 8263658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL
    Prog Clin Biol Res; 1990; 324():137-49. PubMed ID: 2408050
    [No Abstract]   [Full Text] [Related]  

  • 40. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses.
    Wisher M
    Cancer Gene Ther; 2002 Dec; 9(12):1056-61. PubMed ID: 12522444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.